JP2014503567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503567A5 JP2014503567A5 JP2013550833A JP2013550833A JP2014503567A5 JP 2014503567 A5 JP2014503567 A5 JP 2014503567A5 JP 2013550833 A JP2013550833 A JP 2013550833A JP 2013550833 A JP2013550833 A JP 2013550833A JP 2014503567 A5 JP2014503567 A5 JP 2014503567A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- quinazoline
- pyrrolo
- formula
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- -1 - alkyl Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 claims 1
- SNFGHOGDCXZSGY-UHFFFAOYSA-N 2-(4-bromo-2-methoxyanilino)-n-(2,6-diethylphenyl)-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(Br)C=C1OC SNFGHOGDCXZSGY-UHFFFAOYSA-N 0.000 claims 1
- JPYAEEZHLANFOV-UHFFFAOYSA-N 2-(4-bromo-2-methoxyanilino)-n-(2,6-diethylphenyl)-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(Br)C=C1OC JPYAEEZHLANFOV-UHFFFAOYSA-N 0.000 claims 1
- HCUXMELTHAQYDN-MUUNZHRXSA-N 2-(4-bromo-2-methoxyanilino)-n-[(1s)-2-(1,3-dioxoisoindol-2-yl)-1-phenylethyl]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound COC1=CC(Br)=CC=C1NC1=NC=C(CCC2=C3N(C)C=C2C(=O)N[C@H](CN2C(C4=CC=CC=C4C2=O)=O)C=2C=CC=CC=2)C3=N1 HCUXMELTHAQYDN-MUUNZHRXSA-N 0.000 claims 1
- CQNXJSHIMDAHNX-UHFFFAOYSA-N 2-(dimethylamino)-8-methyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(N(C)C)=NC=C2CCC2=C1NC(C)=C2C(N)=O CQNXJSHIMDAHNX-UHFFFAOYSA-N 0.000 claims 1
- NKTVIWIDORBNHH-UHFFFAOYSA-N 2-(dimethylamino)-8-methyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(N(C)C)=NC=C2C=CC2=C1NC(C)=C2C(N)=O NKTVIWIDORBNHH-UHFFFAOYSA-N 0.000 claims 1
- RJGLNSNPZNKTGL-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C=1C=C(NC=2N=C3C=4N(C)C(C)=C(C(N)=O)C=4CCC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RJGLNSNPZNKTGL-UHFFFAOYSA-N 0.000 claims 1
- BWJORBLWBGOLQL-UHFFFAOYSA-N 2-amino-8-phenyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound N1C(C2=NC(N)=NC=C2C=C2)=C2C(C(=O)N)=C1C1=CC=CC=C1 BWJORBLWBGOLQL-UHFFFAOYSA-N 0.000 claims 1
- UXWNPSLXAXDXKK-UHFFFAOYSA-N 2-amino-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1CC2=CN=C(N)N=C2C2=C1C(C(N)=O)=CN2C UXWNPSLXAXDXKK-UHFFFAOYSA-N 0.000 claims 1
- KVWLHWMGSYRLAU-UHFFFAOYSA-N 2-amino-9-methyl-8-phenyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound NC(=O)C=1C=2CCC3=CN=C(N)N=C3C=2N(C)C=1C1=CC=CC=C1 KVWLHWMGSYRLAU-UHFFFAOYSA-N 0.000 claims 1
- OXBHOAOVRFUPJX-UHFFFAOYSA-N 2-amino-9-methyl-8-phenylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound NC(=O)C=1C2=CC=C3C=NC(N)=NC3=C2N(C)C=1C1=CC=CC=C1 OXBHOAOVRFUPJX-UHFFFAOYSA-N 0.000 claims 1
- CCYINSRXXFXUST-UHFFFAOYSA-N 2-methyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(C)=NC=C2CCC2=C1NC=C2C(N)=O CCYINSRXXFXUST-UHFFFAOYSA-N 0.000 claims 1
- YQUFJQISWIFZLH-UHFFFAOYSA-N 2-methylsulfanyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1NC=C2C(N)=O YQUFJQISWIFZLH-UHFFFAOYSA-N 0.000 claims 1
- QZODUKPIHBQCBB-UHFFFAOYSA-N 2-methylsulfanyl-9-piperidin-4-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1C1CCNCC1 QZODUKPIHBQCBB-UHFFFAOYSA-N 0.000 claims 1
- ZWVHBACWMIHSNL-UHFFFAOYSA-N 2-methylsulfanyl-9-piperidin-4-ylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1C1CCNCC1 ZWVHBACWMIHSNL-UHFFFAOYSA-N 0.000 claims 1
- JCICCACMYITOCI-UHFFFAOYSA-N 2-methylsulfanyl-9-propan-2-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(C(C)C)C=C2C(N)=O JCICCACMYITOCI-UHFFFAOYSA-N 0.000 claims 1
- XHEYSFJJPSXTHP-UHFFFAOYSA-N 2-methylsulfanyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1NC=C2C(N)=O XHEYSFJJPSXTHP-UHFFFAOYSA-N 0.000 claims 1
- KGKDUDXNIIDOCV-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1NC(C)=C2C(N)=O KGKDUDXNIIDOCV-UHFFFAOYSA-N 0.000 claims 1
- DGFIPMBMVVDMPR-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-9-propan-2-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(C(C)C)C(C)=C2C(N)=O DGFIPMBMVVDMPR-UHFFFAOYSA-N 0.000 claims 1
- UKHAILBNXALNFF-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1NC(C)=C2C(N)=O UKHAILBNXALNFF-UHFFFAOYSA-N 0.000 claims 1
- IJFXPCHHRYCYMT-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-methylsulfanyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(CCO)C=C2C(N)=O IJFXPCHHRYCYMT-UHFFFAOYSA-N 0.000 claims 1
- MNTKEWDJIACGNK-UHFFFAOYSA-N 9-(2-hydroxyethyl)-8-methyl-2-methylsulfanyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(CCO)C(C)=C2C(N)=O MNTKEWDJIACGNK-UHFFFAOYSA-N 0.000 claims 1
- LVYDNZIZBIQXIS-UHFFFAOYSA-N 9-(2-hydroxyethyl)-8-methyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1N(CCO)C(C)=C2C(N)=O LVYDNZIZBIQXIS-UHFFFAOYSA-N 0.000 claims 1
- JYCIIVNGEUKVMV-UHFFFAOYSA-N 9-(3-amino-2,2-dimethylpropyl)-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide;hydrochloride Chemical compound Cl.C12=NC(SC)=NC=C2C=CC2=C1N(CC(C)(C)CN)C=C2C(N)=O JYCIIVNGEUKVMV-UHFFFAOYSA-N 0.000 claims 1
- JYHABUQXZXZOLO-UHFFFAOYSA-N 9-ethyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=NC(SC)=NC2=C3N(CC)C=C(C(N)=O)C3=CC=C21 JYHABUQXZXZOLO-UHFFFAOYSA-N 0.000 claims 1
- UECMCGVVQAQYOJ-UHFFFAOYSA-N 9-methyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1N(C)C=C2C(N)=O UECMCGVVQAQYOJ-UHFFFAOYSA-N 0.000 claims 1
- CXMXBFQRJAIBDD-UHFFFAOYSA-N 9H-cyclohepta[d]pyrimidine-8-carboxamide Chemical compound N1=CN=CC2=C1CC(=CC=C2)C(=O)N CXMXBFQRJAIBDD-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- FRANNCVVJFQWOT-TXEJJXNPSA-N C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 Chemical compound C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 FRANNCVVJFQWOT-TXEJJXNPSA-N 0.000 claims 1
- BRAYMNJVFKIQLD-TXEJJXNPSA-N C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 Chemical compound C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 BRAYMNJVFKIQLD-TXEJJXNPSA-N 0.000 claims 1
- VTSDHOBIBSBOEN-UHFFFAOYSA-N Cl.CSC1=NC2=C3C(=CC=C2C=N1)C(=CN3)C(=O)N Chemical compound Cl.CSC1=NC2=C3C(=CC=C2C=N1)C(=CN3)C(=O)N VTSDHOBIBSBOEN-UHFFFAOYSA-N 0.000 claims 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 claims 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- GFPDONVWLDXBHG-UHFFFAOYSA-N NC1=NC=2C3=C(CCC2C=N1)C(=CN3C)C(=O)NC3=C(C=C(C=C3)N3CCN(CC3)C)OC Chemical compound NC1=NC=2C3=C(CCC2C=N1)C(=CN3C)C(=O)NC3=C(C=C(C=C3)N3CCN(CC3)C)OC GFPDONVWLDXBHG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- ISJSUWAGGVIHDZ-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(C)CC2)C=C1OC ISJSUWAGGVIHDZ-UHFFFAOYSA-N 0.000 claims 1
- HRLWNUGLIWNXQQ-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N2CCCC2)C=C1OC HRLWNUGLIWNXQQ-UHFFFAOYSA-N 0.000 claims 1
- ILEDQKOHCPIFFS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[3-(dimethylamino)propyl-methylamino]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N(C)CCCN(C)C)C=C1OC ILEDQKOHCPIFFS-UHFFFAOYSA-N 0.000 claims 1
- YXROSHBBKYVTDI-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(CCO)CC2)C=C1OC YXROSHBBKYVTDI-UHFFFAOYSA-N 0.000 claims 1
- LYFDXTJJPSDFMS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(CCO)CC2)C=C1OC LYFDXTJJPSDFMS-UHFFFAOYSA-N 0.000 claims 1
- SWEYDUSNJPBSGO-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N(C)C)C=C1OC SWEYDUSNJPBSGO-UHFFFAOYSA-N 0.000 claims 1
- PTUKZCQTLIICLP-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N(C)C)C=C1OC PTUKZCQTLIICLP-UHFFFAOYSA-N 0.000 claims 1
- GKHAZTHWYXEFJA-UHFFFAOYSA-N n-(2,6-diethylphenyl)-9-(methoxymethyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(COC)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(C)CC2)C=C1OC GKHAZTHWYXEFJA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- TYHCBIKGTCZFTK-UHFFFAOYSA-N quinazoline-7-carboxamide Chemical compound C1=NC=NC2=CC(C(=O)N)=CC=C21 TYHCBIKGTCZFTK-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152190.2 | 2011-01-26 | ||
| EP11152190 | 2011-01-26 | ||
| PCT/EP2012/050773 WO2012101032A1 (en) | 2011-01-26 | 2012-01-19 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203440A Division JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503567A JP2014503567A (ja) | 2014-02-13 |
| JP2014503567A5 true JP2014503567A5 (show.php) | 2015-03-05 |
| JP5925809B2 JP5925809B2 (ja) | 2016-05-25 |
Family
ID=45562287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550833A Active JP5925809B2 (ja) | 2011-01-26 | 2012-01-19 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
| JP2015203440A Active JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203440A Active JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8975267B2 (show.php) |
| EP (1) | EP2668190B1 (show.php) |
| JP (2) | JP5925809B2 (show.php) |
| CN (1) | CN103339134B (show.php) |
| BR (1) | BR112013018515B1 (show.php) |
| ES (1) | ES2602791T3 (show.php) |
| RU (1) | RU2591191C2 (show.php) |
| WO (1) | WO2012101032A1 (show.php) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US8541576B2 (en) * | 2010-12-17 | 2013-09-24 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| ES2602791T3 (es) | 2011-01-26 | 2017-02-22 | Nerviano Medical Sciences S.R.L. | Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa |
| GB201216018D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| DK3129374T3 (en) * | 2014-04-07 | 2019-04-08 | Netherlands Translational Res Center B V | (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| CN107567503B (zh) | 2015-04-17 | 2022-03-22 | 荷兰转化研究中心有限责任公司 | 用于ttk抑制剂化疗的预后生物标记 |
| ITRM20150212A1 (it) * | 2015-05-15 | 2016-11-15 | Univ Degli Studi Di Palermo | 4,5,6,9-tetraidropirrolo[2',3':3,4] cicloepta[1,2-d] isossazoli, procedimento per la loro produzione e loro uso come antitumorali |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| CN105130980B (zh) * | 2015-09-09 | 2018-05-22 | 沈阳药科大学 | N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| BR112018008357A2 (en) | 2015-10-26 | 2018-11-27 | Loxo Oncology, Inc. | dot mutations in trk inhibitor resistant cancer and related methods |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| RS65988B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Postupak lečenja pedijatrijskih karcinoma |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HRP20201984T1 (hr) | 2016-05-18 | 2021-04-16 | Loxo Oncology, Inc. | Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US12428423B2 (en) | 2017-04-01 | 2025-09-30 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| ES2972864T3 (es) * | 2019-08-02 | 2024-06-17 | Chengdu Cynogen Bio Pharmaceutical Tech Co Ltd | Compuestos de 1H-[1,2,3]triazolo[4,5-h]quinazolina que actúan como inhibidores de una proteína cinasa |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| BR112022012684A2 (pt) | 2019-12-27 | 2023-03-07 | Schroedinger Inc | Compostos cíclicos e métodos de uso dos mesmos |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| CN114685520B (zh) * | 2020-12-25 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| WO2023113479A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
| US20250057844A1 (en) * | 2021-12-15 | 2025-02-20 | Sillajen, Inc. | Methods of treating neoplastic diseases |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115833A (en) | 1994-11-25 | 1998-10-27 | Zeneca Ltd | 6,6-Dihalo-3,3-dimethyl-5-hydroxy-7,7,7-trifluoroheptanoic acids and their alkyl esters useful as intermediates for insecticides and their preparation |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2476665A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
| BRPI0410563B8 (pt) * | 2003-05-22 | 2021-05-25 | Nerviano Medical Sciences Srl | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| ES2422299T3 (es) | 2006-11-28 | 2013-09-10 | Nerviano Medical Sciences Srl | Indoles (4,5-dihidro) indoles tricíclicos |
| JP5542445B2 (ja) | 2006-12-04 | 2014-07-09 | 江▲蘇▼先声▲薬▼物研究有限公司 | ３−ピロロシクロへキシリデン−２−ジヒドロインドリノン誘導体およびその用途 |
| EP2125822B1 (en) * | 2006-12-21 | 2014-11-19 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| CA2693904A1 (en) * | 2007-07-16 | 2009-01-22 | Novartis Ag | Heterocyclic compounds useful as mk2 inhibitors |
| EP2240029A4 (en) | 2008-01-07 | 2012-08-22 | Synta Pharmaceuticals Corp | COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES |
| US8546410B2 (en) * | 2008-05-05 | 2013-10-01 | Abbvie Inc. | Heteroaryl-fused macrocyclic pyrimidine derivatives |
| AU2009264431B2 (en) * | 2008-06-26 | 2013-11-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazolines |
| JP5579715B2 (ja) * | 2008-07-29 | 2014-08-27 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ |
| EP2323664B1 (en) * | 2008-07-29 | 2015-01-07 | Nerviano Medical Sciences S.r.l. | Use of a cdk inhibitor for the treatment of glioma |
| CN102223885B (zh) * | 2008-11-24 | 2013-04-03 | 内尔维阿诺医学科学有限公司 | 用于治疗间皮瘤的cdk抑制剂 |
| US8580793B2 (en) * | 2009-03-20 | 2013-11-12 | Nerviano Medical Services S.R.L. | Use of kinase inhibitor for the treatment of thymoma |
| CN102428086B (zh) * | 2009-04-29 | 2014-08-20 | 内尔维阿诺医学科学有限公司 | Cdk抑制剂的盐类 |
| AR076784A1 (es) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| ES2553114T3 (es) * | 2009-07-29 | 2015-12-04 | Nerviano Medical Sciences S.R.L. | Sales de inhibidor de plk |
| WO2012013557A1 (en) * | 2010-07-30 | 2012-02-02 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| US8541576B2 (en) * | 2010-12-17 | 2013-09-24 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| ES2602791T3 (es) | 2011-01-26 | 2017-02-22 | Nerviano Medical Sciences S.R.L. | Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa |
-
2012
- 2012-01-19 ES ES12702207.7T patent/ES2602791T3/es active Active
- 2012-01-19 RU RU2013139353/04A patent/RU2591191C2/ru active
- 2012-01-19 EP EP12702207.7A patent/EP2668190B1/en active Active
- 2012-01-19 WO PCT/EP2012/050773 patent/WO2012101032A1/en not_active Ceased
- 2012-01-19 CN CN201280006541.4A patent/CN103339134B/zh active Active
- 2012-01-19 JP JP2013550833A patent/JP5925809B2/ja active Active
- 2012-01-19 BR BR112013018515-5A patent/BR112013018515B1/pt active IP Right Grant
- 2012-01-19 US US13/980,168 patent/US8975267B2/en active Active
-
2015
- 2015-01-30 US US14/609,534 patent/US9309253B2/en active Active
- 2015-10-15 JP JP2015203440A patent/JP6118383B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503567A5 (show.php) | ||
| JP2016053042A5 (show.php) | ||
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| US11578054B2 (en) | Compounds useful as immunomodulators | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| RU2013139353A (ru) | Трициклические пирролопроизводные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP6898868B2 (ja) | Ｈｐｋ１阻害剤およびそれを用いる方法 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| US20240173307A1 (en) | Modulators of the integrated stress pathway | |
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| KR20180017013A (ko) | K-Ras 조절제 | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| US12090149B2 (en) | SMAD3 inhibitors | |
| WO2016082713A1 (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| JP2016501251A (ja) | がんの治療のための新規二環フェニル−ピリジン／ピラジン | |
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS | |
| KR20220028075A (ko) | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 | |
| US10730878B2 (en) | Fused quinoline compounds as PI3K/mTOR inhibitors | |
| CN103002899A (zh) | 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物 | |
| CN116635390A (zh) | 作为血清素1b受体调节剂的强效和选择性化合物 | |
| JP2016513726A (ja) | がん細胞成長阻害剤としてのテトラヒドロイソキノリン−２−イル−（キナゾリン−４−イル）メタノン化合物 | |
| CN113966329B (zh) | 作为pdl1检查点抑制剂的杂环免疫调节剂 | |
| TWI904095B (zh) | 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑 | |
| CN121399105A (en) | Heteroaromatic DHODH inhibitors |